期刊發表

類別
日期
新藥研發
2019-06
Pharmacokinetic and Toxicokinetic Studies of a Sustained Release Liposomal Formulation of Dexamethasone Sodium Phosphate (TLC599) Following Intra-articular Injection in Dogs
作者 Tzung-Ju Wu, Wan-Ni. Yu, Ming-Ju Wu, Po-Chun Chang, Hui-Ting Wang and Sheue-Fang Shih; Taiwan Liposome Company, Taipei, Taiwan
已發表 歐洲抗風濕病聯盟（EULAR）歐洲科學大會
新藥研發
2019-05
Single Intra-articular Injection of TLC599 Provided Sustained Pain Relief through 24 Weeks in Participants with Symptomatic Knee Osteoarthritis
作者 D. Hunter, C-C. Chang, J-C. Wei, H-Y. Lin, C. Brown, S-F. Shih; Univ. of Sydney, Sydney, Australia, Royal North Shore Hosp., Sydney, Australia, Div. of Allergy, Immunology and Rheumatology, Dept. of Internal Med., Sch. of Med., Coll. of Med., Taipei Med. Univ., Taipei, Taiwan, Div. of Allergy, Immunology and
Rheumatology, Chung Shan Med. Univ. Hosp., Taipei, Taiwan, Dept. of Internal Med., Cheng Hsin Gen. Hosp., Taipei,
Taiwan, Dept. of Allergy, Immunology and Rheumatology, Taipei Veterans Gen. Hosp., Taipei, Taiwan, Taiwan
Liposome Company, Taipei, Taiwan
已發表 2019國際關節炎研討大會(Osteoarthritis Research Society International World Congress, OARSI)
新藥研發
2019-05
Cartilage Damage and Synovial Toxicokinetic Study of a Sustained Release Liposomal Formulation of Dexamethasone Sodium Phosphate (TLC599) following Intra-articular Injection in Healthy Dogs and Rabbits
作者 W-N. Yu, M-J Wu, P-C Chang, S-F Shih; Taiwan Liposome Company, Taipei, Taiwan
已發表 2019國際關節炎研討大會(Osteoarthritis Research Society International World Congress, OARSI)
新藥研發
2018-09
Safety, tolerability, and efficacy of a novel sustained-release liposomal formulation of dexamethasone sodium phosphate (TLC599) in patients with knee osteoarthritis
作者 Chien-Chih Lai, Chao-Ching Chiang, Chyou-Shen Lee, Chi-Ching Chang, Hsiao-Yi Lin, Tien-Ling Chen, and Sheue-Fang Shih
已發表 第20屆亞太風濕病醫學會
癌症相關
臨床研究
2014-06
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors.
作者 Ghamande, S., Lin, C. C., Cho, D. C., Shapiro, G. I., Kwak, E. L., Silverman, M. H., Tseng, Y. L., Kuo, M. W., Mach, W. B., Hsu, S. C., Coleman, T., Yang, J. C., Cheng, A. L., Ghalib, M. H., Chuadhary, I., Goel, S.
已發表 Invest New Drugs.
32(3):445-51, 2014.
癌症相關
非臨床研究
2013-11
Monitoring tumor response with [18F] FMAU in a sarcoma-bearing mouse model after liposomal vinorelbine treatment.
作者 Chan P. C., Wu C. Y., Chang W. T., Lin C. Y., Tseng, Y. L., Liu R. S., Alauddin M. M., Lin W. J., Wang H. E.
已發表 Nucl Med Biol.
40(8):1035-42, 2013.
癌症相關
非臨床研究
傳輸技術
2013-05
Tumor burden talks in cancer treatment with PEGylated liposomal drugs.
作者 Lin Y. Y., Kao H. W., Li J. J., Hwang J. J., Tseng, Y. L., Lin W. J., Lin M. H., Ting G., Wang H. E.
已發表 PLoS One.
10;8(5):e63078, 2013.
癌症相關
臨床研究
2012-02
A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor.
作者 Yang, S. H., Lin, C. C., Lin, Z. Z., Tseng, Y. L., and Hong, R. L.
已發表 Invest New Drugs,
30(1):282-289, 2012.
癌症相關
非臨床研究
傳輸技術
2011-06
Pharmacokinetics and dosimetry of (111) In/(188) Re-labeled PEGylated liposomal drugs in two colon carcinoma-bearing mouse models.
作者 Lin, Y. Y., Chang, C. H., Li, J. J., Stabin, M. G., Chang, Y. J., Chen, L. C., Lin, M. H., Tseng, Y. L., Lin, W. J., Lee, T. W., Ting, G., Chang, C. A., Chen, F. D., Wang, H. E.
已發表 Cancer Biother Radiopharm.,
26(3):373-380, 2011.
癌症相關
非臨床研究
傳輸技術
2009-12
Therapeutic efficacy evaluation of 111In-labeled PEGylated liposomal vinorelbine in murine colon carcinoma with multimodalities of molecular imaging.
作者 Chow, T. H., Lin, Y. Y., Hwang, J. J., Wang, H. E., Tseng, Y. L., Pang, V. F., Liu, R. S., Lin, W. J., Yang, C. S., and Ting, G.
已發表 Nucl. Med.,
50:2073-2081, 2009.
of
2
您即將離開TLC網站

您將前往外部網站，該網站之內容及其維護等將由第三方對其負全部責任。

TLC僅提供此連結予您參考， TLC不對任何第三方網站之隱私政策負責。我們提醒您詳讀您造訪之各網站的隱私政策。

點擊"停留"或右上角關閉視窗以留在此網站，或點擊"繼續"

繼續 停留